Exploring how lung cancer cells present antigens to the immune system
Official title: Interrogating the relationship between translational dynamics and non-canonical antigen presentation in lung cancer
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-10943035 · Data updated 2026-11-12
This study is looking at how lung cancer cells show certain markers to the immune system, especially to important immune cells called CD8+ T cells, to help find new ways to make cancer treatments more effective and personalized for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | July 15, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $485,494 |
| NIH project number | 1R01CA292692-01 |
| Project ID | NIH-10943035 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are lung cancer patients, particularly those with low tumor mutation burdens who may not respond well to traditional therapies.
✕Less likely to help
Patients with cancers that do not involve the mechanisms of antigen presentation being studied may not benefit from this research.
What this research studies
This research investigates how lung cancer cells present specific antigens to the immune system, particularly focusing on CD8+ T cells, which are crucial for targeting cancer. By utilizing advanced mass spectrometry techniques, the study aims to identify a broader range of cancer-specific antigens, including those derived from novel genetic sequences. This approach seeks to enhance the effectiveness of immunotherapies by understanding the diverse sources of antigens that can stimulate immune responses against tumors. Patients may benefit from insights that could lead to more personalized and effective cancer treatments.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy options for lung cancer patients by identifying new targets for treatment.
How similar studies have gone: Previous research has shown promise in identifying novel antigens for immunotherapy, suggesting that this approach could yield significant advancements.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Jaeger, Alex — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Jaeger, Alex
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.